Background and objectives: PCOS affects the endocrine, metabolic, and reproductive systems, resulting in the production of cysts in the women who have it. When provided, D-chiro inositol, a new therapeutic agent, has the potential to enhance the patient's endocrine profile. D-Chiro Inositol is being tested in a new trial to see how well it will help individuals with PCOS reduce their androgen levels.

Methodology of the study: This randomised trial took place in the Department of Medical Sciences' outpatient department from June 2020 to March 2021. A random number generator was used to divide 50 women with polycystic ovarian disorder into two groups of 25 each. While another group found a placebo supplement, one received D-Chiro Inositol (600mg per day). A number of androgens were assessed at the start of treatment and again eight weeks later, including LH, FSH, and testosterone. An independent sample T test was used to compare the therapy effects after eight weeks, with a P value of less than 0.05 declared statistical significance.

Results: D-Chiro Inositol (D-Chiro Inositol) was shown to be more effective than placebo for patients aged 28.8 to 30.9. D-Chiro Inositol women had a mean BMI of 25.73.6 kg/m2, while placebo women had a BMI of 25.84.2 kg/m2. Testosterone levels in the D-Chiro Inositol group were 78.48 ng/dl, 14.74 microIU/ml, and 10.19 microIU/ml, respectively, while these values were 17.22 microIU/ml, 13.03 microIU/ml, and 86.08% in the placebo group. There was a statistically significant difference between the two treatment groups (P value 0.05). D-Chiro Inositol seems to be an effective treatment for polycystic ovarian syndrome since it has the capacity to reduce testosterone levels.